You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFentanyl
Accession NumberDB00813  (APRD00347, DB05853)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational, Vet Approved
DescriptionA potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
Structure
Thumb
Synonyms
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
Fentanil
Fentanila
Fentanilo
Fentanyl
Fentanyl
Fentanylum
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
Phentanyl
External Identifiers
  • McN-JR 4263-49
  • R 4263
  • R 5240
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abstraltablet600 mcgsublingualPaladin Labs Inc2011-06-14Not applicableCanada
Abstraltablet200 ug/1sublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
Abstraltablet300 ug/1sublingualPro Strakan, Inc.2011-01-07Not applicableUs
Abstraltablet800 ug/1sublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
Abstraltablet200 mcgsublingualPaladin Labs Inc2011-04-18Not applicableCanada
Abstraltablet800 mcgsublingualPaladin Labs Inc2011-06-03Not applicableCanada
Abstraltablet300 ug/1sublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
Abstraltablet400 ug/1sublingualPro Strakan, Inc.2011-01-07Not applicableUs
Abstraltablet300 mcgsublingualPaladin Labs Inc2011-04-18Not applicableCanada
Abstraltablet400 ug/1sublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
Abstraltablet100 ug/1sublingualPro Strakan, Inc.2011-01-07Not applicableUs
Abstraltablet600 ug/1sublingualPro Strakan, Inc.2011-01-07Not applicableUs
Abstraltablet100 ug/1sublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
Abstraltablet400 mcgsublingualPaladin Labs Inc2011-04-18Not applicableCanada
Abstraltablet200 ug/1sublingualPro Strakan, Inc.2011-01-07Not applicableUs
Abstraltablet600 ug/1sublingualGalena Biopharma, Inc.2013-08-08Not applicableUs
Abstraltablet100 mcgsublingualPaladin Labs Inc2011-04-18Not applicableCanada
Abstraltablet800 ug/1sublingualPro Strakan, Inc.2011-01-07Not applicableUs
Actiqlozenge200 ug/1oral; transmucosalCephalon, Incorporated1998-11-04Not applicableUs
Actiqlozenge1200 ug/1oral; transmucosalCephalon, Incorporated1998-11-04Not applicableUs
Actiqlozenge400 ug/1oral; transmucosalCephalon, Incorporated1998-11-04Not applicableUs
Actiqlozenge1600 ug/1oral; transmucosalCephalon, Incorporated1998-11-04Not applicableUs
Actiqlozenge600 ug/1oral; transmucosalCephalon, Incorporated1998-11-04Not applicableUs
Actiqlozenge800 ug/1oral; transmucosalCephalon, Incorporated1998-11-04Not applicableUs
Co Fentanylpatch37 mcgtransdermalCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Co Fentanylpatch25 mcgtransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co Fentanylpatch50 mcgtransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co Fentanylpatch75 mcgtransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co Fentanylpatch12 mcgtransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Co Fentanylpatch100 mcgtransdermalCobalt Pharmaceuticals Company2012-10-18Not applicableCanada
Duragesicpatch12.5 ug/htransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
Duragesicpatch100 ug/htransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
Duragesicpatch25 ug/htransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
Duragesicpatch50 ug/htransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
Duragesicpatch75 ug/htransdermalJanssen Pharmaceuticals, Inc.1990-08-07Not applicableUs
Duragesic 100patch100 mcgtransdermalJanssen Inc1992-12-312009-11-24Canada
Duragesic 12patch12 mcgtransdermalJanssen Inc2006-08-012009-11-24Canada
Duragesic 25patch25 mcgtransdermalJanssen Inc1992-12-312009-11-24Canada
Duragesic 50patch50 mcgtransdermalJanssen Inc1992-12-312009-11-24Canada
Duragesic 75patch75 mcgtransdermalJanssen Inc1992-12-312009-11-24Canada
Duragesic Matpatch25 mcgtransdermalJanssen Inc2009-05-11Not applicableCanada
Duragesic Matpatch50 mcgtransdermalJanssen Inc2009-05-11Not applicableCanada
Duragesic Matpatch12.0 mcgtransdermalJanssen Inc2010-03-16Not applicableCanada
Duragesic Matpatch75 mcgtransdermalJanssen Inc2009-05-11Not applicableCanada
Duragesic Matpatch100 mcgtransdermalJanssen Inc2009-05-11Not applicableCanada
Fentanylpatch75 ug/htransdermalSandoz,Inc.2004-10-01Not applicableUs
Fentanylpatch12 ug/1transdermalDispensing Solutions, Inc.2004-10-01Not applicableUs
Fentanylpatch12.5 ug/htransdermalSandoz,Inc.2004-10-01Not applicableUs
Fentanylpatch100 ug/htransdermalSandoz,Inc.2004-10-01Not applicableUs
Fentanylpatch25 ug/htransdermalSandoz,Inc.2004-10-01Not applicableUs
Fentanylpatch12.5 ug/htransdermalbryant ranch prepack2004-10-01Not applicableUs
Fentanylpatch50 ug/htransdermalSandoz,Inc.2004-10-01Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintramuscular; intravenousHospira, Inc.1985-01-12Not applicableUs
Fentanyl Citratelozenge200 ug/1oral; transmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl Citratelozenge200 ug/1oral; transmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl Citratelozenge200 ug/1oral; transmucosalPhysicians Total Care, Inc.2009-04-24Not applicableUs
Fentanyl Citratelozenge1200 ug/1oral; transmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl Citratelozenge1200 ug/1oral; transmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl Citratelozenge400 ug/1oral; transmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl Citratelozenge400 ug/1oral; transmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl Citrateinjection50 ug/mLintramuscular; intravenousAkorn, Inc.2012-03-22Not applicableUs
Fentanyl Citratelozenge600 ug/1oral; transmucosalPhysicians Total Care, Inc.2009-04-24Not applicableUs
Fentanyl Citratelozenge1600 ug/1oral; transmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl Citratelozenge1600 ug/1oral; transmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl Citratelozenge600 ug/1oral; transmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl Citratelozenge600 ug/1oral; transmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl Citratelozenge800 ug/1oral; transmucosalPhysicians Total Care, Inc.2009-04-24Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintramuscular; intravenousHospira, Inc.1985-01-12Not applicableUs
Fentanyl Citratelozenge400 ug/1oral; transmucosalPhysicians Total Care, Inc.2008-12-19Not applicableUs
Fentanyl Citratelozenge800 ug/1oral; transmucosalTeva Pharmaceuticals USA Inc2015-11-18Not applicableUs
Fentanyl Citratelozenge800 ug/1oral; transmucosalCima Labs Inc.1999-01-20Not applicableUs
Fentanyl Citratelozenge1200 ug/1oral; transmucosalPhysicians Total Care, Inc.2009-06-05Not applicableUs
Fentanyl Citrate Injectionsolution50 mcgintramuscular; intravenous; epiduralHospira Healthcare Corporation1989-12-31Not applicableCanada
Fentanyl Citrate Injection Sdzliquid50 mcgintramuscular; intravenous; epiduralSandoz Canada Incorporated2013-02-21Not applicableCanada
Fentanyl Citrate Injection U.S.P.-liq IV Im Epdsolution50 mcgintramuscular; intravenous; epiduralHospira Healthcare Corporation1997-07-302011-08-05Canada
Fentanyl Citrate Injection USPsolution50 mcgintramuscular; intravenous; epiduralAlveda Pharmaceuticals Inc2016-04-18Not applicableCanada
Fentanyl Citrate Injection USPliquid50 mcgintramuscular; intravenous; epiduralSandoz Canada Incorporated2000-02-10Not applicableCanada
Fentanyl Citrate Injection USP 50mcg/mlliquid50 mcgintramuscular; intravenous; epiduralDavid Bull Laboratories (Canada) Inc.1993-12-311999-08-04Canada
Fentanyl Patchpatch12 mcgtransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl Patchpatch100 mcgtransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl Patchpatch25 mcgtransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl Patchpatch50 mcgtransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl Patchpatch75 mcgtransdermalPro Doc Limitee2012-11-22Not applicableCanada
Fentanyl Transdermal System 100patch (extended release)100 mcgtransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
Fentanyl Transdermal System 25patch (extended release)25 mcgtransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
Fentanyl Transdermal System 50patch (extended release)50 mcgtransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
Fentanyl Transdermal System 75patch (extended release)75 mcgtransdermalActavis Group Ptc EhfNot applicableNot applicableCanada
Fentoratablet600 ug/1buccal; oral; transmucosalCephalon, Inc.2006-09-25Not applicableUs
Fentoratablet (effervescent)200 mcgbuccal; sublingualTeva Canada Limited2014-05-14Not applicableCanada
Fentoratablet800 ug/1buccal; oral; transmucosalCephalon, Inc.2006-09-25Not applicableUs
Fentoratablet100 ug/1buccal; oral; transmucosalCephalon, Inc.2006-09-25Not applicableUs
Fentoratablet (effervescent)400 mcgbuccal; sublingualTeva Canada Limited2014-05-14Not applicableCanada
Fentoratablet200 ug/1buccal; oral; transmucosalCephalon, Inc.2006-09-25Not applicableUs
Fentoratablet (effervescent)600 mcgbuccal; sublingualTeva Canada Limited2014-05-14Not applicableCanada
Fentoratablet (effervescent)100 mcgbuccal; sublingualTeva Canada Limited2014-05-14Not applicableCanada
Fentoratablet (effervescent)800 mcgbuccal; sublingualTeva Canada Limited2014-05-14Not applicableCanada
Fentoratablet400 ug/1buccal; oral; transmucosalCephalon, Inc.2006-09-25Not applicableUs
Instanylsolution50 mcgnasalTakeda Canada IncNot applicableNot applicableCanada
Instanylsolution200 mcgnasalTakeda Canada IncNot applicableNot applicableCanada
Instanylsolution100 mcgnasalTakeda Canada IncNot applicableNot applicableCanada
Ionsyspatch40 ug/1transdermalThe Medicines Company2015-06-01Not applicableUs
Lazandaspray300 ug/1nasalDepomed, Inc.2016-01-01Not applicableUs
Lazandaspray100 ug/1nasalArchimedes Pharma US Inc.2011-10-17Not applicableUs
Lazandaspray100 ug/1nasalDepomed, Inc.2011-10-17Not applicableUs
Lazandaspray400 ug/1nasalArchimedes Pharma US Inc.2011-10-17Not applicableUs
Lazandaspray400 ug/1nasalDepomed, Inc.2011-10-17Not applicableUs
Mylan-fentanyl Matrix Patchpatch50 mcgtransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix Patchpatch75 mcgtransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix Patchpatch12 mcgtransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix Patchpatch100 mcgtransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Mylan-fentanyl Matrix Patchpatch25 mcgtransdermalMylan Pharmaceuticals Ulc2012-11-20Not applicableCanada
Onsolisfilm, soluble800 mcgbuccalMeda Ab2011-08-222013-01-31Canada
Onsolisfilm, soluble200 mcgbuccalMeda Ab2011-08-222013-01-31Canada
Onsolisfilm, soluble1200 mcgbuccalMeda Ab2011-08-222013-01-31Canada
Onsolisfilm, soluble400 mcgbuccalMeda Ab2011-08-222013-01-31Canada
Onsolisfilm, soluble600 mcgbuccalMeda Ab2011-08-222013-01-31Canada
Pat-fentanyl Matpatch50 mcgtransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl Matpatch75 mcgtransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl Matpatch12.0 mcgtransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl Matpatch100 mcgtransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-fentanyl Matpatch25 mcgtransdermalPatriot A Division Of Janssen IncNot applicableNot applicableCanada
PMS-fentanyl Mtxpatch50 mcgtransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl Mtxpatch75 mcgtransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl Mtxpatch100 mcgtransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl Mtxpatch12 mcgtransdermalPharmascience Inc2010-03-18Not applicableCanada
PMS-fentanyl Mtxpatch25 mcgtransdermalPharmascience Inc2010-03-18Not applicableCanada
Ran-fentanyl Matrix Patchpatch12 mcgtransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix Patchpatch100 mcgtransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix Patchpatch25 mcgtransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix Patchpatch50 mcgtransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Matrix Patchpatch75 mcgtransdermalRanbaxy Pharmaceuticals Canada Inc.2009-09-28Not applicableCanada
Ran-fentanyl Transdermal Systempatch7.5 mgtransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Ran-fentanyl Transdermal Systempatch10 mgtransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Ran-fentanyl Transdermal Systempatch2.5 mgtransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Ran-fentanyl Transdermal Systempatch5 mgtransdermalRanbaxy Pharmaceuticals Canada Inc.2006-07-112011-08-12Canada
Sandoz Fentanyl Patchpatch50 mcgtransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl Patchpatch12 mcgtransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl Patchpatch75 mcgtransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl Patchpatch25 mcgtransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl Patchpatch100 mcgtransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sandoz Fentanyl Patchpatch37 mcgtransdermalSandoz Canada Incorporated2010-11-01Not applicableCanada
Sublimaze Inj 50mcg/mlliquid50 mcgintramuscular; intravenous; epiduralJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1987-12-311996-09-10Canada
Subsysspray.6 mg/1sublingualInsys Therapeutics, Inc.2012-08-30Not applicableUs
Subsysspray.4 mg/1sublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
Subsysspray.8 mg/1sublingualInsys Therapeutics, Inc.2012-08-30Not applicableUs
Subsysspray.6 mg/1sublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
Subsysspray.1 mg/1sublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
Subsysspray.8 mg/1sublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
Subsysspray.2 mg/1sublingualInsys Therapeutics, Inc.2012-03-13Not applicableUs
Teva-fentanylpatch12 mcgtransdermalTeva Canada Limited2008-06-27Not applicableCanada
Teva-fentanylpatch25 mcgtransdermalTeva Canada Limited2006-07-04Not applicableCanada
Teva-fentanylpatch50 mcgtransdermalTeva Canada Limited2006-07-04Not applicableCanada
Teva-fentanylpatch75 mcgtransdermalTeva Canada Limited2006-07-04Not applicableCanada
Teva-fentanylpatch100 mcgtransdermalTeva Canada Limited2006-07-04Not applicableCanada
Transmucosal Fentanyl Citratelozenge600 ug/1oral; transmucosalH.J. Harkins Company, Inc.2006-09-06Not applicableUs
Transmucosal Fentanyl Citratelozenge400 ug/1oral; transmucosalH.J. Harkins Company, Inc.2006-09-06Not applicableUs
Transmucosal Fentanyl Citratelozenge1200 1/1oral; transmucosalH.J. Harkins Company, Inc.2006-09-06Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fentanyl Matrixpatch100 mcgtransdermalApotex Inc2009-05-13Not applicableCanada
Apo-fentanyl Matrixpatch25 mcgtransdermalApotex Inc2009-05-13Not applicableCanada
Apo-fentanyl Matrixpatch50 mcgtransdermalApotex Inc2009-05-13Not applicableCanada
Apo-fentanyl Matrixpatch75 mcgtransdermalApotex Inc2009-05-13Not applicableCanada
Apo-fentanyl Matrixpatch12 mcgtransdermalApotex IncNot applicableNot applicableCanada
Fentanylpatch25 ug/htransdermalDAVA Pharmaceuticals, Inc.2010-11-01Not applicableUs
Fentanylpatch, extended release12 ug/htransdermalApotex Corp.2016-01-22Not applicableUs
Fentanylpatch75 ug/htransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
Fentanylpatch, extended release7.5 mg/72htransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-09Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch100 ug/htransdermalSt. Marys Medical Park Pharmacy2011-01-26Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalbryant ranch prepack2007-09-01Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
Fentanylpatch, extended release25 ug/htransdermalTeva Pharmaceuticals USA Inc2008-12-222016-03-29Us
Fentanylpatch12 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2013-01-09Not applicableUs
Fentanylpatch1.28 mg/[USP'U]transdermalPhysicians Total Care, Inc.2008-11-18Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
Fentanylpatch87.5 ug/htransdermalMylan Pharmaceuticals Inc.2015-02-24Not applicableUs
Fentanylpatch2.55 mg/[USP'U]transdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalbryant ranch prepack2013-04-04Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalDispensing Solutions Inc.2006-11-06Not applicableUs
Fentanylpatch12 ug/htransdermalMylan Pharmaceuticals Inc.2007-01-24Not applicableUs
Fentanylpatch100 ug/htransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalApotex Corp.2010-03-01Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalbryant ranch prepack2010-03-01Not applicableUs
Fentanylpatch50 ug/htransdermalDAVA Pharmaceuticals, Inc.2010-11-01Not applicableUs
Fentanylpatch100 ug/htransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
Fentanylpatch, extended release2.5 mg/72htransdermalSTAT Rx USA LLC2007-08-20Not applicableUs
Fentanylpatch, extended release10 mg/72htransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-09Not applicableUs
Fentanylpatch25 ug/htransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalApotex Corp.2010-03-01Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalDIRECT RX2015-01-01Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalbryant ranch prepack2007-09-01Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
Fentanylpatch, extended release50 ug/htransdermalTeva Pharmaceuticals USA Inc2008-12-222016-03-29Us
Fentanylpatch100 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2013-01-09Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
Fentanylpatch5.1 mg/[USP'U]transdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalbryant ranch prepack2013-04-04Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalDispensing Solutions Inc.2006-11-06Not applicableUs
Fentanylpatch25 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2005-01-28Not applicableUs
Fentanylpatch25 ug/htransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
Fentanylpatch, extended release2.5 mg/72htransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-09Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalbryant ranch prepack2010-03-01Not applicableUs
Fentanylpatch, extended release5 mg/72htransdermalSTAT Rx USA LLC2007-08-20Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalH.J. Harkins Company, Inc.2010-03-01Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalbryant ranch prepack2010-03-01Not applicableUs
Fentanylpatch75 ug/htransdermalDAVA Pharmaceuticals, Inc.2010-11-01Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
Fentanylpatch37.5 ug/htransdermalMylan Pharmaceuticals Inc.2015-02-24Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalTeva Pharmaceuticals USA Inc2008-10-202016-03-29Us
Fentanylpatch50 ug/htransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalApotex Corp.2010-03-01Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalDIRECT RX2015-01-01Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
Fentanylpatch7.65 mg/[USP'U]transdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
Fentanylpatch25 ug/htransdermalSt. Marys Medical Park Pharmacy2011-01-26Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalbryant ranch prepack2007-09-01Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalDispensing Solutions Inc.2006-11-06Not applicableUs
Fentanylpatch87.5 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2015-02-24Not applicableUs
Fentanylpatch50 ug/htransdermalMylan Pharmaceuticals Inc.2005-01-28Not applicableUs
Fentanylpatch, extended release5 mg/72htransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-09Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch50 ug/htransdermalCorium International, Inc.2007-08-20Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalActavis Pharma, Inc.2007-09-01Not applicableUs
Fentanylpatch62.5 ug/htransdermalMylan Pharmaceuticals Inc.2015-02-24Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalH.J. Harkins Company, Inc.2010-03-01Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalApotex Corp.2013-04-04Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalbryant ranch prepack2013-04-04Not applicableUs
Fentanylpatch100 ug/htransdermalDAVA Pharmaceuticals, Inc.2010-11-01Not applicableUs
Fentanylpatch, extended release100 ug/htransdermalTeva Pharmaceuticals USA Inc2008-10-202016-03-29Us
Fentanylpatch75 ug/htransdermalPar Pharmaceutical Inc.2007-08-20Not applicableUs
Fentanylpatch, extended release75 ug/htransdermalApotex Corp.2010-03-01Not applicableUs
Fentanylpatch, extended release50 ug/htransdermalbryant ranch prepack2010-03-01Not applicableUs
Fentanylpatch10.2 mg/[USP'U]transdermalPhysicians Total Care, Inc.2005-07-14Not applicableUs
Fentanylpatch50 ug/htransdermalSt. Marys Medical Park Pharmacy2011-01-26Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalbryant ranch prepack2007-09-01Not applicableUs
Fentanylpatch, extended release25 ug/htransdermalUpsher Smith Laboratories, Inc.2013-03-012015-12-31Us
Fentanyl - Novapluspatch, extended release50 ug/htransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl - Novapluspatch, extended release75 ug/htransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl - Novapluspatch, extended release100 ug/htransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl - Novapluspatch, extended release25 ug/htransdermalWatson Laboratories, Inc.2007-09-01Not applicableUs
Fentanyl Buccaltablet400 ug/1buccal; oral; transmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl Buccaltablet600 ug/1buccal; oral; transmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl Buccaltablet800 ug/1buccal; oral; transmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl Buccaltablet100 ug/1buccal; oral; transmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl Buccaltablet200 ug/1buccal; oral; transmucosalWatson Laboratories, Inc.2011-01-07Not applicableUs
Fentanyl Citratelozenge1600 ug/1transmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl Citrateinjection50 ug/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl Citratelozenge1600 ug/1oral; transmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl Citrateinjection50 ug/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl Citratelozenge400 ug/1oral; transmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl Citratelozenge600 ug/1transmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintramuscular; intravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl Citrateinjection, solution50 ug/mLintramuscular; intravenousHospira, Inc.1991-09-24Not applicableUs
Fentanyl Citrateinjection50 ug/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl Citrateinjection50 ug/mLintravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl Citratelozenge600 ug/1oral; transmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl Citratelozenge800 ug/1transmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintramuscular; intravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl Citrateinjection50 ug/mLintravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl Citratelozenge200 ug/1transmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl Citrateinjection50 ug/mLintravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl Citratelozenge800 ug/1oral; transmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl Citratelozenge1200 ug/1transmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl Citratelozenge800 ug/1oral; transmucosalLake Erie Medical DBA Quality Care Products LLC2011-10-17Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintramuscular; intravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl Citrateinjection50 ug/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1984-07-11Not applicableUs
Fentanyl Citratelozenge200 ug/1oral; transmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl Citratelozenge400 ug/1transmucosalMallinckrodt Inc.2010-01-15Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintramuscular; intravenousBaxter Healthcare Corporation2010-06-252015-12-29Us
Fentanyl Citratelozenge1200 ug/1oral; transmucosalPar Pharmaceutical Inc.2011-10-17Not applicableUs
Fentanyl Transdermal Systempatch, extended release50 ug/htransdermalRebel Distributors Corp.2011-02-09Not applicableUs
Fentanyl Transdermal Systempatch, extended release75 ug/htransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release50 ug/htransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release75 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release100 ug/htransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release25 ug/htransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release75 ug/htransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release100 ug/htransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release100 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release100 ug/htransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release25 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release50 ug/htransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release12.5 ug/htransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release50 ug/htransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release50 ug/htransdermalLake Erie Medical DBA Quality Care Products LLC2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release75 ug/htransdermalbryant ranch prepack2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release25 ug/htransdermalMallinckrodt, Inc.2011-06-06Not applicableUs
Fentanyl Transdermal Systempatch, extended release25 ug/htransdermalRebel Distributors Corp2011-02-09Not applicableUs
PecfentNasal spray, solution100 μg / sprayNasal useArchimedes Development Ltd2010-08-31Not applicableEu
PecfentNasal spray, solution100 μg / sprayNasal useArchimedes Development Ltd2010-08-31Not applicableEu
PecfentNasal spray, solution100 μg / sprayNasal useArchimedes Development Ltd2010-08-31Not applicableEu
PecfentNasal spray, solution400 μg / sprayNasal useArchimedes Development Ltd2010-08-31Not applicableEu
PecfentNasal spray, solution400 μg / sprayNasal useArchimedes Development Ltd2010-08-31Not applicableEu
PecfentNasal spray, solution100 μg / sprayNasal useArchimedes Development Ltd2010-08-31Not applicableEu
PecfentNasal spray, solution400 μg / sprayNasal useArchimedes Development Ltd2010-08-31Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fentanyl Citrateinjection, solution10 ug/mLintravenousCantrell Drug Company2011-07-26Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintravenousCantrell Drug Company2013-03-14Not applicableUs
Fentanyl Citrateinjection, solution20 ug/mLintravenousCantrell Drug Company2013-01-30Not applicableUs
Fentanyl Citrateinjection, solution5 ug/mLintravenousCantrell Drug Company2013-11-22Not applicableUs
Fentanyl Citrateinjection, solution25 ug/mLintravenousCantrell Drug Company2012-10-19Not applicableUs
Fentanyl Citrateinjection, solution50 ug/mLintravenousCantrell Drug Company2011-10-20Not applicableUs
IonsysIontophoretic transdermal system40 μg/doseTransdermal UseJanssen Cilag International Nv2006-01-24Not applicableEu
International Brands
NameCompany
DurogesicJanssen
FentanestPfizer
NasalfentArchimedes
RapinylGedeon Richter
Brand mixtures
NameLabellerIngredients
Fentanyl Citrate, Bupivacaine HClCantrell Drug Company
Innovar InjJanssen Pharmaceutica, Division Of Janssen Ortho Inc.
Salts
Name/CASStructureProperties
Fentanyl citrate
990-73-8
Thumb
  • InChI Key: IVLVTNPOHDFFCJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 528.247166138
  • Average Mass: 528.594
DBSALT000301
Fentanyl hydrochloride
ThumbNot applicableDBSALT001226
Categories
UNIIUF599785JZ
CAS number437-38-7
WeightAverage: 336.4705
Monoisotopic: 336.220163528
Chemical FormulaC22H28N2O
InChI KeyInChIKey=PJMPHNIQZUBGLI-UHFFFAOYSA-N
InChI
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
IUPAC Name
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
SMILES
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as fentanyls. These are compounds containing the fentanyl moiety or a derivative, which is based on a N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassFentanyls
Direct ParentFentanyls
Alternative Parents
Substituents
  • Fentanyl
  • Anilide
  • Phenethylamine
  • Aralkylamine
  • 4-aminopiperidine
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
PharmacodynamicsFentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor but also binds to kappa and delta-type opioid receptors. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.
Mechanism of actionOpiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hypopolarization and reduced neuronal excitability.
Related Articles
AbsorptionBioavailability is 92% following transdermal administration and 50% following buccal administration.
Volume of distribution
  • 3 to 8 L/kg [Surgical Patients]
  • 0.8 to 8 [Hepatically Impaired Patients]
Protein binding80-85%
Metabolism

Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system.

SubstrateEnzymesProduct
Fentanyl
norfentanylDetails
Route of eliminationFentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and mostly eliminated in urine. Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug.
Half life7 hours (range 3-12)
Clearance
  • 27 – 75 L/h [Surgical Patients receving IV administration]
  • 3 – 80 L/h [Hepatically Impaired Patients receving IV administration]
  • 30 – 78 L/h [Renally Impaired Patients receving IV administration]
ToxicityFentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans is not known.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fentanyl Action PathwayDrug actionSMP00415
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9766
Blood Brain Barrier+0.9901
Caco-2 permeable+0.6459
P-glycoprotein substrateSubstrate0.6082
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.8371
Renal organic cation transporterInhibitor0.5824
CYP450 2C9 substrateNon-substrate0.7879
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5856
CYP450 1A2 substrateNon-inhibitor0.7715
CYP450 2C9 inhibitorNon-inhibitor0.873
CYP450 2D6 inhibitorNon-inhibitor0.6327
CYP450 2C19 inhibitorNon-inhibitor0.5724
CYP450 3A4 inhibitorNon-inhibitor0.8218
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7346
Ames testNon AMES toxic0.8417
CarcinogenicityNon-carcinogens0.8536
BiodegradationNot ready biodegradable0.8554
Rat acute toxicity3.9836 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.796
hERG inhibition (predictor II)Inhibitor0.6791
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Actavis southatlantic llc
  • Lavipharm laboratories inc
  • Mylan technologies inc
  • Noven pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Meda pharmaceuticals inc
  • Abbott laboratories hosp products div
  • Hospira inc
  • Baxter healthcare corp anesthesia and critical care
  • Marsam pharmaceuticals llc
  • Akorn inc
  • Cephalon inc
  • Barr laboratories inc
  • Mallinckrodt inc
  • Incline therapeutics inc
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Tabletsublingual100 ug/1
Tabletsublingual100 mcg
Tabletsublingual200 ug/1
Tabletsublingual200 mcg
Tabletsublingual300 ug/1
Tabletsublingual300 mcg
Tabletsublingual400 mcg
Tabletsublingual400 ug/1
Tabletsublingual600 ug/1
Tabletsublingual600 mcg
Tabletsublingual800 ug/1
Tabletsublingual800 mcg
Patchtransdermal100 mcg
Patchtransdermal12.0 mcg
Patchtransdermal25 mcg
Patchtransdermal50 mcg
Patchtransdermal75 mcg
Patchtransdermal1.28 mg/[USP'U]
Patchtransdermal10.2 mg/[USP'U]
Patchtransdermal100 ug/h
Patchtransdermal12 ug/h
Patchtransdermal12 ug/1
Patchtransdermal12.5 ug/h
Patchtransdermal2.55 mg/[USP'U]
Patchtransdermal25 ug/h
Patchtransdermal37.5 ug/h
Patchtransdermal5.1 mg/[USP'U]
Patchtransdermal50 ug/h
Patchtransdermal62.5 ug/h
Patchtransdermal7.65 mg/[USP'U]
Patchtransdermal75 ug/h
Patchtransdermal87.5 ug/h
Patch, extended releasetransdermal10 mg/72h
Patch, extended releasetransdermal100 ug/h
Patch, extended releasetransdermal12 ug/h
Patch, extended releasetransdermal2.5 mg/72h
Patch, extended releasetransdermal25 ug/h
Patch, extended releasetransdermal5 mg/72h
Patch, extended releasetransdermal50 ug/h
Patch, extended releasetransdermal7.5 mg/72h
Patch, extended releasetransdermal75 ug/h
Tabletbuccal; oral; transmucosal100 ug/1
Tabletbuccal; oral; transmucosal200 ug/1
Tabletbuccal; oral; transmucosal400 ug/1
Tabletbuccal; oral; transmucosal600 ug/1
Tabletbuccal; oral; transmucosal800 ug/1
Injectionintramuscular; intravenous50 ug/mL
Injectionintravenous50 ug/mL
Injection, solutionintramuscular; intravenous50 ug/mL
Injection, solutionintravenous10 ug/mL
Injection, solutionintravenous20 ug/mL
Injection, solutionintravenous25 ug/mL
Injection, solutionintravenous5 ug/mL
Injection, solutionintravenous50 ug/mL
Lozengeoral; transmucosal1200 ug/1
Lozengeoral; transmucosal1600 ug/1
Lozengeoral; transmucosal200 ug/1
Lozengeoral; transmucosal400 ug/1
Lozengeoral; transmucosal600 ug/1
Lozengeoral; transmucosal800 ug/1
Lozengetransmucosal1200 ug/1
Lozengetransmucosal1600 ug/1
Lozengetransmucosal200 ug/1
Lozengetransmucosal400 ug/1
Lozengetransmucosal600 ug/1
Lozengetransmucosal800 ug/1
Solutionintramuscular; intravenous; epidural50 mcg
Liquidintramuscular; intravenous; epidural50 mcg
Injection, solutionepidural
Patch, extended releasetransdermal12.5 ug/h
Patch (extended release)transdermal100 mcg
Patch (extended release)transdermal25 mcg
Patch (extended release)transdermal50 mcg
Patch (extended release)transdermal75 mcg
Tablet (effervescent)buccal; sublingual100 mcg
Tablet (effervescent)buccal; sublingual200 mcg
Tablet (effervescent)buccal; sublingual400 mcg
Tablet (effervescent)buccal; sublingual600 mcg
Tablet (effervescent)buccal; sublingual800 mcg
Liquidintramuscular; intravenous
Solutionnasal100 mcg
Solutionnasal200 mcg
Solutionnasal50 mcg
Iontophoretic transdermal systemTransdermal Use40 μg/dose
Patchtransdermal40 ug/1
Spraynasal100 ug/1
Spraynasal300 ug/1
Spraynasal400 ug/1
Film, solublebuccal1200 mcg
Film, solublebuccal200 mcg
Film, solublebuccal400 mcg
Film, solublebuccal600 mcg
Film, solublebuccal800 mcg
Nasal spray, solutionNasal use100 μg / spray
Nasal spray, solutionNasal use400 μg / spray
Patchtransdermal10 mg
Patchtransdermal2.5 mg
Patchtransdermal5 mg
Patchtransdermal7.5 mg
Patchtransdermal37 mcg
Spraysublingual.1 mg/1
Spraysublingual.2 mg/1
Spraysublingual.4 mg/1
Spraysublingual.6 mg/1
Spraysublingual.8 mg/1
Patchtransdermal12 mcg
Lozengeoral; transmucosal1200 1/1
Prices
Unit descriptionCostUnit
Fentanyl base powder1498.18USD g
Fentanyl citrate powder1062.5USD g
Duragesic-100 5 100 mcg/hr Patches Box411.59USD box
Duragesic-75 5 75 mcg/hr Patches Box318.93USD box
Fentanyl 5 100 mcg/hr Patches Box210.0USD box
Duragesic-50 5 50 mcg/hr Patches Box205.78USD box
Actiq 1600 mcg lozenge150.29USD lozenge
Fentanyl 5 50 mcg/hr Patches Box129.99USD box
Actiq 1200 mcg lozenge121.82USD lozenge
Actiq 1600 mcg Lollipop119.42USD lollipop
Duragesic-25 5 25 mcg/hr Patches Box114.42USD box
Duragesic-12 5 12 mcg/hr Patches Box95.99USD box
Actiq 800 mcg lozenge93.76USD lozenge
Actiq 1200 mcg Lollipop85.7USD lollipop
Duragesic 100 mcg/hr patch81.36USD patch
Actiq 600 mcg lozenge79.16USD lozenge
Actiq 800 mcg Lollipop75.98USD lollipop
Fentanyl 5 12 (12.5)mcg/hr Patches Box67.99USD box
Fentanyl 5 25 mcg/hr Patches Box66.66USD box
Actiq 600 mcg Lollipop65.13USD lollipop
Actiq 400 mcg lozenge64.62USD lozenge
Fentanyl 100 mcg/hr patch61.69USD patch
Duragesic 75 mcg/hr patch61.3USD patch
Fentora 800 mcg buccal tablet54.77USD tablet
Actiq 400 mcg Lollipop53.75USD lollipop
Actiq 200 mcg lozenge51.05USD lozenge
Fentora 600 mcg buccal tablet47.37USD tablet
Fentanyl 75 mcg/hr patch46.48USD patch
Actiq 200 mcg Lollipop42.14USD lollipop
Duragesic 50 mcg/hr patch40.19USD patch
FentaNYL Citrate 1600 mcg Lollipop38.53USD lollipop
Fentora 400 mcg buccal tablet34.24USD tablet
Fentanyl 50 mcg/hr patch30.47USD patch
FentaNYL Citrate 1200 mcg Lollipop30.0USD lollipop
Fentora 300 mcg buccal tablet28.84USD tablet
Fentora 200 mcg buccal tablet23.57USD tablet
Duragesic 25 mcg/hr patch21.98USD patch
FentaNYL Citrate 400 mcg Lollipop20.0USD lollipop
Fentora 100 mcg buccal tablet18.64USD tablet
Duragesic 12 mcg/hr patch18.21USD patch
Fentanyl 25 mcg/hr patch16.67USD patch
Fentanyl 12 mcg/hr patch13.8USD patch
Fentanyl 0.05 mg/ml vial1.96USD ml
Fentanyl cit 1500 mcg/30 ml1.44USD ml
Fentanyl-ns 50 mcg/ml syringe1.0USD ml
Fentanyl-ns 300 mcg/30 ml syr0.99USD ml
Fentanyl-ns 20 mcg/ml syringe0.72USD ml
Fentanyl-ns 10 mcg/ml syringe0.64USD ml
Fentanyl cit 2750 mcg/55 ml0.35USD ml
Fentanyl-ns 500 mcg/50 ml syr0.31USD ml
Sublimaze 0.05 mg/ml ampul0.23USD ml
Fentanyl 0.05 mg/ml ampul0.21USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5697896 No1996-12-162016-12-16Us
US5843014 No1995-12-012015-12-01Us
US6159498 No1996-10-182016-10-18Us
US6169920 No1998-01-022018-01-02Us
US6181963 No1999-11-022019-11-02Us
US6195582 No1999-01-282019-01-28Us
US6200604 No1999-03-262019-03-26Us
US6317629 No1995-06-022012-06-02Us
US6432440 No1998-04-202018-04-20Us
US6759059 No1999-09-242019-09-24Us
US6761910 No1999-09-242019-09-24Us
US6881208 No2002-04-192022-04-19Us
US6974590 No1999-03-262019-03-26Us
US6975902 No2004-04-012024-04-01Us
US7579019 No2000-01-222020-01-22Us
US7862832 No2008-06-152028-06-15Us
US7862833 No2008-06-152028-06-15Us
US7910132 No1999-09-242019-09-24Us
US8092832 No2004-12-302024-12-30Us
US8119158 No2004-12-302024-12-30Us
US8216604 No2004-10-032024-10-03Us
US8301238 No2011-09-302031-09-30Us
US8428708 No2012-05-212032-05-21Us
US8428709 No2012-06-112032-06-11Us
US8486972 No2010-04-272030-04-27Us
US8486973 No2010-04-272030-04-27Us
US8728441 No1999-03-262019-03-26Us
US8753611 No1999-03-262019-03-26Us
US8765100 No1999-03-262019-03-26Us
US8781571 No2012-03-312032-03-31Us
US8835459 No2007-01-252027-01-25Us
US8835460 No2007-01-252027-01-25Us
US8889176 No2004-01-162024-01-16Us
US9078814 No2004-01-082024-01-08Us
US9095706 No2013-02-032033-02-03Us
US9241935 No2007-01-252027-01-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point83-84 US. Patent 3,141,823.
water solubility200 mg/L (at 25 °C)ROY,SD & FLYNN,GL (1988)
logP4.05SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.024 mg/mLALOGPS
logP4.12ALOGPS
logP3.82ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.48 m3·mol-1ChemAxon
Polarizability40.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9850000000-7ce3a6f35f5dee98185fView in MoNA
References
Synthesis Reference

Mark Rubino, “Process of making fentanyl intermediates.” U.S. Patent US20060100438, issued May 11, 2006.

US20060100438
General References
  1. Van Bever WF, Niemegeers CJ, Janssen PA: Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. J Med Chem. 1974 Oct;17(10):1047-51. [PubMed:4420811 ]
  2. Messina J, Darwish M, Fine PG: Fentanyl buccal tablet. Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. [PubMed:18301803 ]
  3. Taylor DR: Fentanyl buccal tablet: rapid relief from breakthrough pain. Expert Opin Pharmacother. 2007 Dec;8(17):3043-51. [PubMed:18001263 ]
  4. Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Apr;29(4):588-601. [PubMed:17617282 ]
External Links
ATC CodesN01AH51N01AH01N02AB03
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (507 KB)
MSDSDownload (75.5 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Fentanyl.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Fentanyl.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with 7-Nitroindazole.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fentanyl.
AcepromazineAcepromazine may increase the hypotensive activities of Fentanyl.
AcepromazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Fentanyl.
AcetazolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Fentanyl.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Fentanyl.
adipiplonThe risk or severity of adverse effects can be increased when Fentanyl is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fentanyl.
AgomelatineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fentanyl.
AlfaxaloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fentanyl.
AlimemazineAlimemazine may increase the hypotensive activities of Fentanyl.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fentanyl.
AlmotriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Almotriptan.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fentanyl.
AlvimopanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alvimopan.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fentanyl.
AmilorideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amiloride.
AmiodaroneThe serum concentration of Fentanyl can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Fentanyl.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fentanyl.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Fentanyl which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amobarbital.
AmoxapineFentanyl may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fentanyl.
AmperozideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Fentanyl.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fentanyl.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fentanyl.
AprepitantThe serum concentration of Fentanyl can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Fentanyl.
ArticaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Asenapine.
AtazanavirThe serum concentration of Fentanyl can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fentanyl.
AtomoxetineThe metabolism of Fentanyl can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fentanyl.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Fentanyl.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fentanyl.
AzaperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azaperone.
AzelastineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fentanyl.
AzosemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Fentanyl.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Fentanyl.
BenzocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Fentanyl.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fentanyl.
BexaroteneThe serum concentration of Fentanyl can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bifeprunox.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Fentanyl.
BoceprevirThe serum concentration of Fentanyl can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Fentanyl can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Fentanyl can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fentanyl.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fentanyl.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
BrimonidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Fentanyl.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fentanyl.
BrompheniramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fentanyl.
BuprenorphineBuprenorphine may decrease the analgesic activities of Fentanyl.
BuprenorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fentanyl.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fentanyl.
ButacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Fentanyl.
ButorphanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fentanyl.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fentanyl.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Fentanyl.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fentanyl.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Fentanyl.
Canrenoic acidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Canrenoic acid.
CarbamazepineThe serum concentration of Fentanyl can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Fentanyl.
CarbinoxamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fentanyl.
CariprazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carisoprodol.
CeritinibThe serum concentration of Fentanyl can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fentanyl.
CetirizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fentanyl.
ChlormezanoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Fentanyl.
ChlorphentermineChlorphentermine may increase the analgesic activities of Fentanyl.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Fentanyl.
ChlorpromazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorzoxazone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Fentanyl.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fentanyl.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fentanyl.
CirazolineThe serum concentration of Fentanyl can be decreased when it is combined with Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fentanyl.
CitalopramFentanyl may increase the serotonergic activities of Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Fentanyl.
ClarithromycinThe serum concentration of Fentanyl can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Fentanyl can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Fentanyl.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fentanyl.
clomethiazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fentanyl.
ClomipramineFentanyl may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fentanyl.
ClonazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Fentanyl.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fentanyl.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Fentanyl.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fentanyl.
ClotrimazoleThe metabolism of Fentanyl can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clozapine.
CobicistatThe serum concentration of Fentanyl can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fentanyl.
CocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fentanyl.
ConivaptanThe serum concentration of Fentanyl can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fentanyl.
CrizotinibThe serum concentration of Fentanyl can be increased when it is combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fentanyl.
CyclosporineThe metabolism of Fentanyl can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fentanyl.
CyclothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fentanyl.
DabrafenibThe serum concentration of Fentanyl can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Fentanyl.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fentanyl.
DantroleneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Fentanyl.
DapiprazoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fentanyl.
DapoxetineFentanyl may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Fentanyl.
DarunavirThe serum concentration of Fentanyl can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Fentanyl can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fentanyl.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fentanyl.
DeferasiroxThe serum concentration of Fentanyl can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Fentanyl can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Fentanyl is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fentanyl.
DesmopressinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Detomidine.
DexamethasoneThe serum concentration of Fentanyl can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Fentanyl.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Fentanyl.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fentanyl.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Fentanyl.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fentanyl.
DextromoramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fentanyl.
DezocineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fentanyl.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fentanyl.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fentanyl.
DifenoxinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fentanyl.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fentanyl.
DihydrocodeineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Fentanyl can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fentanyl.
DiltiazemThe metabolism of Fentanyl can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Fentanyl.
DimenhydrinateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fentanyl.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fentanyl.
DolasetronDolasetron may increase the serotonergic activities of Fentanyl.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fentanyl.
DoramectinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fentanyl.
DoxycyclineThe metabolism of Fentanyl can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
DoxylamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Fentanyl is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
DronedaroneThe metabolism of Fentanyl can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Droperidol.
DrospirenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fentanyl.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fentanyl.
EcgonineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Fentanyl is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fentanyl.
EfavirenzThe serum concentration of Fentanyl can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Fentanyl.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fentanyl.
EluxadolineFentanyl may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fentanyl.
EntacaponeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Entacapone.
EnzalutamideThe serum concentration of Fentanyl can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Fentanyl.
EplerenoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Eplerenone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergonovine.
ErgotamineThe serum concentration of Fentanyl can be decreased when it is combined with Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fentanyl.
ErythromycinThe metabolism of Fentanyl can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Fentanyl.
EscitalopramFentanyl may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fentanyl.
Eslicarbazepine acetateThe serum concentration of Fentanyl can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fentanyl.
EstriolThe serum concentration of Estriol can be increased when it is combined with Fentanyl.
EstroneThe serum concentration of Estrone can be increased when it is combined with Fentanyl.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fentanyl.
Etacrynic acidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid.
EthanolFentanyl may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fentanyl.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fentanyl.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fentanyl.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Fentanyl.
EthosuximideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fentanyl.
EtoperidoneFentanyl may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fentanyl.
EtorphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etorphine.
EtravirineThe serum concentration of Fentanyl can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fentanyl.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fentanyl.
EzogabineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fencamfamine.
FenfluramineFentanyl may increase the serotonergic activities of Fenfluramine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fentanyl.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fentanyl.
FlibanserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flibanserin.
FluconazoleThe metabolism of Fentanyl can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunitrazepam.
FluoxetineFentanyl may increase the serotonergic activities of Fluoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fentanyl.
FlupentixolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Fentanyl.
FluphenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fentanyl.
FluspirileneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fentanyl.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluticasone Propionate.
FluvoxamineFentanyl may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Fentanyl can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Fentanyl can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Fentanyl can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fentanyl can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Frovatriptan.
FurosemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide.
Fusidic AcidThe serum concentration of Fentanyl can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fentanyl is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Fentanyl.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fentanyl.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fentanyl.
GlutethimideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Fentanyl.
GranisetronGranisetron may increase the serotonergic activities of Fentanyl.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fentanyl.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Fentanyl.
GuanfacineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fentanyl.
HaloperidolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Fentanyl.
HexobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Fentanyl.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fentanyl.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Fentanyl.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
HydroxyzineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fentanyl.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fentanyl.
IdelalisibThe serum concentration of Fentanyl can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Iloperidone.
ImatinibThe metabolism of Fentanyl can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Fentanyl.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Fentanyl.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fentanyl.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Fentanyl.
IndalpineFentanyl may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide.
IndinavirThe serum concentration of Fentanyl can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fentanyl.
Ioflupane I-123Fentanyl may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fentanyl.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fentanyl.
IsavuconazoniumThe metabolism of Fentanyl can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fentanyl.
IsosorbideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isosorbide.
IsradipineThe metabolism of Fentanyl can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Fentanyl can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Fentanyl can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fentanyl.
KetamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Fentanyl.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fentanyl.
KetobemidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketobemidone.
KetoconazoleThe serum concentration of Fentanyl can be increased when it is combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Fentanyl is combined with KW-3902.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fentanyl.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fentanyl.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fentanyl.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fentanyl.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fentanyl.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fentanyl.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Fentanyl.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fentanyl.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fentanyl.
LevobupivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fentanyl.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomethadyl Acetate.
LevomilnacipranFentanyl may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fentanyl.
LevorphanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fentanyl.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fentanyl.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fentanyl.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Fentanyl.
LithiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Fentanyl.
LopinavirThe serum concentration of Fentanyl can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fentanyl.
LorcaserinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Fentanyl.
LovastatinThe metabolism of Fentanyl can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Loxapine.
Lu AA21004Fentanyl may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Fentanyl.
LuliconazoleThe serum concentration of Fentanyl can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fentanyl.
MeclizineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Fentanyl is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Melperone.
MephentermineThe serum concentration of Fentanyl can be decreased when it is combined with Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl.
MersalylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Fentanyl.
MesoridazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mesoridazine.
MetaraminolThe serum concentration of Fentanyl can be decreased when it is combined with Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fentanyl.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Fentanyl.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Fentanyl.
MethapyrileneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fentanyl.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fentanyl.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Fentanyl.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methotrimeprazine.
MethoxamineThe serum concentration of Fentanyl can be decreased when it is combined with Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Fentanyl.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fentanyl.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Fentanyl.
MetoclopramideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metoclopramide.
MetolazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fentanyl.
MetyrosineFentanyl may increase the sedative activities of Metyrosine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fentanyl.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fentanyl.
MidodrineThe serum concentration of Fentanyl can be decreased when it is combined with Midodrine.
MifepristoneThe serum concentration of Fentanyl can be increased when it is combined with Mifepristone.
MilnacipranFentanyl may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Fentanyl.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Fentanyl.
MirtazapineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fentanyl.
MitotaneThe serum concentration of Fentanyl can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fentanyl.
MoclobemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Moclobemide.
ModafinilThe serum concentration of Fentanyl can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Fentanyl.
MorphineThe serum concentration of Morphine can be increased when it is combined with Fentanyl.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fentanyl.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fentanyl.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Fentanyl.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
NabiloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Fentanyl.
NafcillinThe serum concentration of Fentanyl can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Fentanyl.
NalbuphineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fentanyl.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Fentanyl.
NaltrexoneThe therapeutic efficacy of Fentanyl can be decreased when used in combination with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Naratriptan.
NefazodoneThe serum concentration of Fentanyl can be increased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nefazodone.
NelfinavirThe serum concentration of Fentanyl can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Fentanyl can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Fentanyl can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Fentanyl.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Fentanyl.
NilotinibThe metabolism of Fentanyl can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Fentanyl.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fentanyl.
NitrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fentanyl.
NormethadoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Fentanyl.
OlanzapineFentanyl may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fentanyl.
OlaparibThe metabolism of Fentanyl can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fentanyl.
OndansetronThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Fentanyl.
OpiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Opium.
OrphenadrineFentanyl may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fentanyl.
OsanetantThe risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant.
OsimertinibThe serum concentration of Fentanyl can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Fentanyl.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl.
OxymorphoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fentanyl.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fentanyl.
PalbociclibThe serum concentration of Fentanyl can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Fentanyl.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fentanyl.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Fentanyl.
ParaldehydeFentanyl may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fentanyl.
ParoxetineFentanyl may increase the serotonergic activities of Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fentanyl.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fentanyl.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.
PentazocinePentazocine may decrease the analgesic activities of Fentanyl.
PentazocineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pentazocine.
PentobarbitalThe serum concentration of Fentanyl can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fentanyl.
PerampanelThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Fentanyl.
PerphenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fentanyl.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fentanyl.
PhenobarbitalThe serum concentration of Fentanyl can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Fentanyl.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Fentanyl.
PhenylephrineThe serum concentration of Fentanyl can be decreased when it is combined with Phenylephrine.
PhenytoinThe serum concentration of Fentanyl can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fentanyl.
PimozideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fentanyl.
PipotiazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fentanyl.
PiretanideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piretanide.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fentanyl.
PizotifenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fentanyl.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fentanyl.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Fentanyl.
PosaconazoleThe serum concentration of Fentanyl can be increased when it is combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium Citrate.
PramipexoleFentanyl may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fentanyl.
PrazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fentanyl.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fentanyl.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fentanyl.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fentanyl.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fentanyl.
PrimidoneThe serum concentration of Fentanyl can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fentanyl.
ProcarbazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Procarbazine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Fentanyl.
ProchlorperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fentanyl.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Fentanyl.
PromazinePromazine may increase the hypotensive activities of Fentanyl.
PromazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Fentanyl.
PromethazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Fentanyl.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fentanyl.
PropericiazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fentanyl.
ProtriptylineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fentanyl.
PSD502The risk or severity of adverse effects can be increased when Fentanyl is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Fentanyl.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Fentanyl.
QuinineThe serum concentration of Quinine can be increased when it is combined with Fentanyl.
RamelteonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ramelteon.
RamosetronFentanyl may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fentanyl.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fentanyl.
RanolazineThe metabolism of Fentanyl can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Reserpine.
RifabutinThe serum concentration of Fentanyl can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Fentanyl can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Fentanyl.
RifapentineThe serum concentration of Fentanyl can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fentanyl.
RisperidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Risperidone.
RitonavirThe serum concentration of Fentanyl can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fentanyl.
RizatriptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rizatriptan.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Fentanyl.
RomifidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Romifidine.
RopiniroleFentanyl may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fentanyl.
RotigotineFentanyl may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fentanyl.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Fentanyl is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fentanyl.
SaquinavirThe serum concentration of Fentanyl can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fentanyl.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Fentanyl.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fentanyl.
SelegilineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fentanyl.
SertindoleThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sertindole.
SertralineFentanyl may increase the serotonergic activities of Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Fentanyl.
SevofluraneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sevoflurane.
SildenafilThe metabolism of Fentanyl can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fentanyl.
SiltuximabThe serum concentration of Fentanyl can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Fentanyl can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Fentanyl.
Sodium oxybateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fentanyl.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Fentanyl.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Fentanyl.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fentanyl.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fentanyl.
SpironolactoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Spironolactone.
St. John's WortThe serum concentration of Fentanyl can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Fentanyl.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.
SulfisoxazoleThe metabolism of Fentanyl can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fentanyl.
SuvorexantThe risk or severity of adverse effects can be increased when Fentanyl is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Fentanyl.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Fentanyl.
TapentadolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fentanyl.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fentanyl.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fentanyl.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Fentanyl can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Fentanyl can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fentanyl.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fentanyl.
TetrabenazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrodotoxin.
ThalidomideFentanyl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fentanyl.
TheobromineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Fentanyl.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fentanyl.
ThioproperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thioproperazine.
ThioridazineThioridazine may increase the hypotensive activities of Fentanyl.
ThioridazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fentanyl.
TiclopidineThe metabolism of Fentanyl can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Fentanyl.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Fentanyl.
TizanidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tizanidine.
TocilizumabThe serum concentration of Fentanyl can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Fentanyl.
TolvaptanThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Fentanyl is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fentanyl.
TorasemideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Fentanyl.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fentanyl.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fentanyl.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fentanyl.
TrazodoneFentanyl may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fentanyl.
TriamtereneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Fentanyl.
TrifluoperazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Fentanyl.
TriflupromazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fentanyl.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fentanyl.
TrimipramineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fentanyl.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Fentanyl.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fentanyl.
UlaritideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ularitide.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fentanyl.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Fentanyl.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fentanyl.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fentanyl.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fentanyl.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fentanyl.
VenlafaxineThe metabolism of Fentanyl can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Fentanyl.
VerapamilThe metabolism of Fentanyl can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Fentanyl.
VigabatrinThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vigabatrin.
VilazodoneFentanyl may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fentanyl.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fentanyl.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fentanyl.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fentanyl.
VoriconazoleThe serum concentration of Fentanyl can be increased when it is combined with Voriconazole.
VortioxetineFentanyl may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fentanyl.
XylazineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Fentanyl.
ZimelidineFentanyl may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziprasidone.
ZiprasidoneThe metabolism of Fentanyl can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fentanyl.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fentanyl.
ZonisamideThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. [PubMed:15589524 ]
  2. Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. [PubMed:16114980 ]
  3. Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. [PubMed:16332149 ]
  4. Dosen-Micovic L, Ivanovic M, Micovic V: Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem. 2006 May 1;14(9):2887-95. Epub 2006 Jan 11. [PubMed:16376082 ]
  5. Dardonville C, Fernandez-Fernandez C, Gibbons SL, Ryan GJ, Jagerovic N, Gabilondo AM, Meana JJ, Callado LF: Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Bioorg Med Chem. 2006 Oct 1;14(19):6570-80. Epub 2006 Jun 23. [PubMed:16797997 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [PubMed:19403616 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18. [PubMed:15665994 ]
  2. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74. [PubMed:15828941 ]
  3. Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200. [PubMed:15868528 ]
  4. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86. [PubMed:16372825 ]
  5. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14. [PubMed:16861092 ]
  6. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [PubMed:19403616 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC: Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008 May;33(4):478-86. doi: 10.1016/j.psyneuen.2008.01.006. Epub 2008 Mar 5. [PubMed:18325678 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20. [PubMed:11964599 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:35